SK287568B6 - Kompozícia s trvalým uvoľňovaním, spôsob jej výroby, jej použitie, farmaceutický prípravok a spôsob výroby polyméru - Google Patents

Kompozícia s trvalým uvoľňovaním, spôsob jej výroby, jej použitie, farmaceutický prípravok a spôsob výroby polyméru Download PDF

Info

Publication number: SK287568B6
Authority: SK; Slovakia
Prior art keywords: sustained release; polymer; salt; release composition; molecular weight
Prior art date: 2001-06-29

Application number

SK1561-2003A

Other languages

English (en)

Slovak (sk)

Other versions

SK15612003A3 (sk

Inventor

Kazumichi Yamamoto

Akiko Yamada

Yoshio Hata

Original Assignee

Takeda Pharmaceutical Company Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-06-29

Filing date

2002-06-28

Publication date

2011-02-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26617908&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK287568(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-06-28 Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited

2004-07-07 Publication of SK15612003A3 publication Critical patent/SK15612003A3/sk

2011-02-04 Publication of SK287568B6 publication Critical patent/SK287568B6/sk

Links

229920000642 polymer Polymers 0.000 title claims abstract description 106
239000000203 mixture Substances 0.000 title claims abstract description 81
238000013268 sustained release Methods 0.000 title claims abstract description 65
239000012730 sustained-release form Substances 0.000 title claims abstract description 65
238000000034 method Methods 0.000 title claims description 44
238000004519 manufacturing process Methods 0.000 title claims description 19
239000000825 pharmaceutical preparation Substances 0.000 title 1
150000003839 salts Chemical class 0.000 claims abstract description 74
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 65
XBBVURRQGJPTHH-UHFFFAOYSA-N 2-hydroxyacetic acid;2-hydroxypropanoic acid Chemical compound OCC(O)=O.CC(O)C(O)=O XBBVURRQGJPTHH-UHFFFAOYSA-N 0.000 claims abstract description 46
229920000159 gelatin Polymers 0.000 claims abstract description 11
235000019322 gelatine Nutrition 0.000 claims abstract description 11
239000003094 microcapsule Substances 0.000 claims description 82
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 66
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 64
239000003960 organic solvent Substances 0.000 claims description 49
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 36
239000004310 lactic acid Substances 0.000 claims description 33
235000014655 lactic acid Nutrition 0.000 claims description 33
239000003795 chemical substances by application Substances 0.000 claims description 25
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 20
239000011859 microparticle Substances 0.000 claims description 18
239000004005 microsphere Substances 0.000 claims description 17
239000013543 active substance Substances 0.000 claims description 16
230000008569 process Effects 0.000 claims description 16
239000000243 solution Substances 0.000 claims description 15
239000003814 drug Substances 0.000 claims description 14
229940079593 drug Drugs 0.000 claims description 13
239000008194 pharmaceutical composition Substances 0.000 claims description 11
206010006187 Breast cancer Diseases 0.000 claims description 10
208000026310 Breast neoplasm Diseases 0.000 claims description 10
108010010803 Gelatin Proteins 0.000 claims description 10
239000008273 gelatin Substances 0.000 claims description 10
235000011852 gelatine desserts Nutrition 0.000 claims description 10
239000007864 aqueous solution Substances 0.000 claims description 9
206010028980 Neoplasm Diseases 0.000 claims description 8
239000002904 solvent Substances 0.000 claims description 8
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 7
208000005171 Dysmenorrhea Diseases 0.000 claims description 7
206010013935 Dysmenorrhoea Diseases 0.000 claims description 7
201000009273 Endometriosis Diseases 0.000 claims description 7
206010060862 Prostate cancer Diseases 0.000 claims description 7
208000000236 Prostatic Neoplasms Diseases 0.000 claims description 7
206010046798 Uterine leiomyoma Diseases 0.000 claims description 7
201000011510 cancer Diseases 0.000 claims description 7
238000002347 injection Methods 0.000 claims description 7
239000007924 injection Substances 0.000 claims description 7
230000002028 premature Effects 0.000 claims description 7
230000002265 prevention Effects 0.000 claims description 6
238000001356 surgical procedure Methods 0.000 claims description 5
206010057654 Breast cancer female Diseases 0.000 claims description 4
125000003301 D-leucyl group Chemical group N[C@@H](C(=O)*)CC(C)C 0.000 claims description 4
206010051482 Prostatomegaly Diseases 0.000 claims description 4
125000000030 D-alanine group Chemical group [H]N([H])[C@](C([H])([H])[H])(C(=O)[*])[H] 0.000 claims description 3
125000002437 D-histidyl group Chemical group N[C@@H](C(=O)*)CC=1N=CNC1 0.000 claims description 3
125000000734 D-serino group Chemical group [H]N([H])[C@@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 3
QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims description 3
239000003433 contraceptive agent Substances 0.000 claims description 3
238000002156 mixing Methods 0.000 claims description 3
230000002254 contraceptive effect Effects 0.000 claims description 2
229940124558 contraceptive agent Drugs 0.000 claims 1
239000001828 Gelatine Substances 0.000 abstract 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 33
239000000839 emulsion Substances 0.000 description 20
239000008346 aqueous phase Substances 0.000 description 19
239000003921 oil Substances 0.000 description 17
235000019198 oils Nutrition 0.000 description 17
108010091748 peptide A Proteins 0.000 description 17
238000001035 drying Methods 0.000 description 16
238000009472 formulation Methods 0.000 description 14
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 13
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
229930195725 Mannitol Natural products 0.000 description 13
239000000594 mannitol Substances 0.000 description 13
235000010355 mannitol Nutrition 0.000 description 13
239000012071 phase Substances 0.000 description 13
238000002360 preparation method Methods 0.000 description 12
-1 4H 2 -furoyl Chemical group 0.000 description 11
230000000052 comparative effect Effects 0.000 description 11
239000012153 distilled water Substances 0.000 description 10
230000009477 glass transition Effects 0.000 description 10
238000010438 heat treatment Methods 0.000 description 10
230000003204 osmotic effect Effects 0.000 description 10
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
150000001298 alcohols Chemical class 0.000 description 9
239000002585 base Substances 0.000 description 9
230000001419 dependent effect Effects 0.000 description 9
201000010099 disease Diseases 0.000 description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
229940014259 gelatin Drugs 0.000 description 9
IUVCFHHAEHNCFT-INIZCTEOSA-N 2-[(1s)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1[C@@H](C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 IUVCFHHAEHNCFT-INIZCTEOSA-N 0.000 description 8
239000003163 gonadal steroid hormone Substances 0.000 description 8
239000002253 acid Substances 0.000 description 7
235000001014 amino acid Nutrition 0.000 description 7
150000001413 amino acids Chemical class 0.000 description 7
239000000843 powder Substances 0.000 description 7
230000001105 regulatory effect Effects 0.000 description 7
229920002134 Carboxymethyl cellulose Polymers 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
239000001768 carboxy methyl cellulose Substances 0.000 description 6
235000010948 carboxy methyl cellulose Nutrition 0.000 description 6
239000008112 carboxymethyl-cellulose Substances 0.000 description 6
229940105329 carboxymethylcellulose Drugs 0.000 description 6
229920001577 copolymer Polymers 0.000 description 6
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 6
229920000053 polysorbate 80 Polymers 0.000 description 6
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 5
239000006185 dispersion Substances 0.000 description 5
238000005227 gel permeation chromatography Methods 0.000 description 5
239000002245 particle Substances 0.000 description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
239000004372 Polyvinyl alcohol Substances 0.000 description 4
206010036618 Premenstrual syndrome Diseases 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
150000001412 amines Chemical class 0.000 description 4
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
230000037396 body weight Effects 0.000 description 4
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
239000002612 dispersion medium Substances 0.000 description 4
238000009826 distribution Methods 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
230000000694 effects Effects 0.000 description 4
239000003995 emulsifying agent Substances 0.000 description 4
238000004108 freeze drying Methods 0.000 description 4
XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical class C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 4
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 4
229940068968 polysorbate 80 Drugs 0.000 description 4
229920002451 polyvinyl alcohol Polymers 0.000 description 4
229940068984 polyvinyl alcohol Drugs 0.000 description 4
102000004196 processed proteins & peptides Human genes 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
238000003756 stirring Methods 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
201000000736 Amenorrhea Diseases 0.000 description 3
206010001928 Amenorrhoea Diseases 0.000 description 3
239000004475 Arginine Substances 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine group Chemical group N[C@H](CCCCN)C(=O)O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
208000002495 Uterine Neoplasms Diseases 0.000 description 3
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
229910052783 alkali metal Inorganic materials 0.000 description 3
150000001340 alkali metals Chemical class 0.000 description 3
229910052784 alkaline earth metal Inorganic materials 0.000 description 3
150000001342 alkaline earth metals Chemical class 0.000 description 3
231100000540 amenorrhea Toxicity 0.000 description 3
235000009697 arginine Nutrition 0.000 description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
239000011575 calcium Substances 0.000 description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
229910052802 copper Inorganic materials 0.000 description 3
239000010949 copper Substances 0.000 description 3
238000001704 evaporation Methods 0.000 description 3
239000008103 glucose Substances 0.000 description 3
239000005556 hormone Substances 0.000 description 3
229940088597 hormone Drugs 0.000 description 3
150000007529 inorganic bases Chemical class 0.000 description 3
229910052749 magnesium Inorganic materials 0.000 description 3
239000011777 magnesium Substances 0.000 description 3
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
150000002772 monosaccharides Chemical class 0.000 description 3
229920001542 oligosaccharide Polymers 0.000 description 3
150000002482 oligosaccharides Chemical class 0.000 description 3
150000007530 organic bases Chemical class 0.000 description 3
230000002611 ovarian Effects 0.000 description 3
COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
238000006068 polycondensation reaction Methods 0.000 description 3
229910052700 potassium Inorganic materials 0.000 description 3
239000011591 potassium Substances 0.000 description 3
239000008213 purified water Substances 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
239000011734 sodium Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
208000011580 syndromic disease Diseases 0.000 description 3
239000002562 thickening agent Substances 0.000 description 3
206010046766 uterine cancer Diseases 0.000 description 3
235000015112 vegetable and seed oil Nutrition 0.000 description 3
239000008158 vegetable oil Substances 0.000 description 3
229910052725 zinc Inorganic materials 0.000 description 3
239000011701 zinc Substances 0.000 description 3
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
150000008575 L-amino acids Chemical class 0.000 description 2
QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical group OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
229920001214 Polysorbate 60 Polymers 0.000 description 2
239000004793 Polystyrene Substances 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
239000003377 acid catalyst Substances 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
229920003232 aliphatic polyester Polymers 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
239000004327 boric acid Substances 0.000 description 2
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
235000005687 corn oil Nutrition 0.000 description 2
239000002285 corn oil Substances 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
150000002016 disaccharides Chemical class 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
239000012530 fluid Substances 0.000 description 2
239000012458 free base Substances 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
150000002402 hexoses Chemical class 0.000 description 2
208000000509 infertility Diseases 0.000 description 2
230000036512 infertility Effects 0.000 description 2
231100000535 infertility Toxicity 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
238000005259 measurement Methods 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
239000002480 mineral oil Substances 0.000 description 2
235000010446 mineral oil Nutrition 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
229910017604 nitric acid Inorganic materials 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
229920002223 polystyrene Polymers 0.000 description 2
235000019260 propionic acid Nutrition 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
239000013049 sediment Substances 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
238000001694 spray drying Methods 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
229960003604 testosterone Drugs 0.000 description 2
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
150000004043 trisaccharides Chemical class 0.000 description 2
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
DFZVZEMNPGABKO-SSDOTTSWSA-N (2r)-2-amino-3-pyridin-3-ylpropanoic acid Chemical group OC(=O)[C@H](N)CC1=CC=CN=C1 DFZVZEMNPGABKO-SSDOTTSWSA-N 0.000 description 1
XIGSAGMEBXLVJJ-RXMQYKEDSA-N (2r)-2-azaniumyl-6-(carbamoylamino)hexanoate Chemical group NC(=O)NCCCC[C@@H]([NH3+])C([O-])=O XIGSAGMEBXLVJJ-RXMQYKEDSA-N 0.000 description 1
UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 1
SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
AWIOOXLYLWTJMX-UHFFFAOYSA-N 2-(oxolane-2-carbonylamino)acetic acid Chemical group OC(=O)CNC(=O)C1CCCO1 AWIOOXLYLWTJMX-UHFFFAOYSA-N 0.000 description 1
MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical class C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
JPZXHKDZASGCLU-GFCCVEGCSA-N 3-(2-Naphthyl)-D-Alanine Chemical group C1=CC=CC2=CC(C[C@@H](N)C(O)=O)=CC=C21 JPZXHKDZASGCLU-GFCCVEGCSA-N 0.000 description 1
DBTMGCOVALSLOR-UHFFFAOYSA-N 32-alpha-galactosyl-3-alpha-galactosyl-galactose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(OC2C(C(CO)OC(O)C2O)O)OC(CO)C1O DBTMGCOVALSLOR-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
101000904177 Clupea pallasii Gonadoliberin-1 Proteins 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
RHGKLRLOHDJJDR-SCSAIBSYSA-N D-citrulline Chemical group OC(=O)[C@H](N)CCCNC(N)=O RHGKLRLOHDJJDR-SCSAIBSYSA-N 0.000 description 1
RXVWSYJTUUKTEA-UHFFFAOYSA-N D-maltotriose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 RXVWSYJTUUKTEA-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
102100037815 Fas apoptotic inhibitory molecule 3 Human genes 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
102000009123 Fibrin Human genes 0.000 description 1
108010073385 Fibrin Proteins 0.000 description 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
102100034190 Glypican-1 Human genes 0.000 description 1
NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical class C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 1
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
241001326189 Gyrodactylus prostae Species 0.000 description 1
101000878510 Homo sapiens Fas apoptotic inhibitory molecule 3 Proteins 0.000 description 1
101001070736 Homo sapiens Glypican-1 Proteins 0.000 description 1
LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
229930064664 L-arginine Natural products 0.000 description 1
235000014852 L-arginine Nutrition 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
108010000817 Leuprolide Proteins 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
125000003047 N-acetyl group Chemical group 0.000 description 1
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
206010036590 Premature baby Diseases 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
229920002385 Sodium hyaluronate Polymers 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 1
MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
238000005054 agglomeration Methods 0.000 description 1
230000004931 aggregating effect Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
239000003945 anionic surfactant Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
229920002988 biodegradable polymer Polymers 0.000 description 1
239000004621 biodegradable polymer Substances 0.000 description 1
239000012620 biological material Substances 0.000 description 1
238000009835 boiling Methods 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
238000010908 decantation Methods 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
230000002542 deteriorative effect Effects 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
239000000499 gel Substances 0.000 description 1
229960002442 glucosamine Drugs 0.000 description 1
229940097043 glucuronic acid Drugs 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical compound NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 description 1
239000008187 granular material Substances 0.000 description 1
150000008282 halocarbons Chemical class 0.000 description 1
239000007902 hard capsule Substances 0.000 description 1
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
229920002674 hyaluronan Polymers 0.000 description 1
229960003160 hyaluronic acid Drugs 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
238000002955 isolation Methods 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
229960004338 leuprorelin Drugs 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000000944 linseed oil Substances 0.000 description 1
235000021388 linseed oil Nutrition 0.000 description 1
239000007788 liquid Substances 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
FYGDTMLNYKFZSV-UHFFFAOYSA-N mannotriose Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(O)C(O)C2O)CO)C(O)C1O FYGDTMLNYKFZSV-UHFFFAOYSA-N 0.000 description 1
239000000463 material Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
239000002609 medium Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
239000012053 oil suspension Substances 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000002972 pentoses Chemical class 0.000 description 1
230000035699 permeability Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
238000005191 phase separation Methods 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
235000019422 polyvinyl alcohol Nutrition 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
230000005855 radiation Effects 0.000 description 1
MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
239000002994 raw material Substances 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
238000007151 ring opening polymerisation reaction Methods 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
229920002545 silicone oil Polymers 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
229940010747 sodium hyaluronate Drugs 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
YFGAFXCSLUUJRG-WCCKRBBISA-M sodium;(2s)-2-amino-5-(diaminomethylideneamino)pentanoate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCCN=C(N)N YFGAFXCSLUUJRG-WCCKRBBISA-M 0.000 description 1
YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 1
239000008107 starch Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000010414 supernatant solution Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
150000004044 tetrasaccharides Chemical class 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229910052723 transition metal Inorganic materials 0.000 description 1
150000003624 transition metals Chemical class 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
238000005303 weighing Methods 0.000 description 1
239000008096 xylene Substances 0.000 description 1
239000000811 xylitol Substances 0.000 description 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1
229960002675 xylitol Drugs 0.000 description 1
FYGDTMLNYKFZSV-BYLHFPJWSA-N β-1,4-galactotrioside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H](CO)O[C@@H](O[C@@H]2[C@@H](O[C@@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-BYLHFPJWSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Epidemiology (AREA)
Immunology (AREA)
Diabetes (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Neurosurgery (AREA)
Gynecology & Obstetrics (AREA)
Neurology (AREA)
Gastroenterology & Hepatology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Urology & Nephrology (AREA)
Pregnancy & Childbirth (AREA)
Hospice & Palliative Care (AREA)
Inorganic Chemistry (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SK1561-2003A 2001-06-29 2002-06-28 Kompozícia s trvalým uvoľňovaním, spôsob jej výroby, jej použitie, farmaceutický prípravok a spôsob výroby polyméru SK287568B6 (sk)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2001199462		2001-06-29
JP2001340980		2001-11-06
PCT/JP2002/006526 WO2003002091A2 (en)	2001-06-29	2002-06-28	Sustained-release composition comprising lactic acid-glycolic acid copolymer and process for producing the same

Publications (2)

Publication Number	Publication Date
SK15612003A3 SK15612003A3 (sk)	2004-07-07
SK287568B6 true SK287568B6 (sk)	2011-02-04

Family

ID=26617908

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1561-2003A SK287568B6 (sk)	2001-06-29	2002-06-28	Kompozícia s trvalým uvoľňovaním, spôsob jej výroby, jej použitie, farmaceutický prípravok a spôsob výroby polyméru

Country Status (31)

Country	Link
US (3)	US20040241229A1 (es)
EP (2)	EP1399133B2 (es)
JP (3)	JP5491318B2 (es)
KR (3)	KR20090096755A (es)
CN (1)	CN1535141B (es)
AR (1)	AR034640A1 (es)
AT (1)	ATE429903T1 (es)
AU (1)	AU2002311630B2 (es)
BR (1)	BR0210572A (es)
CA (1)	CA2451718C (es)
CO (1)	CO5540368A2 (es)
CY (1)	CY1109272T1 (es)
CZ (1)	CZ306388B6 (es)
DE (1)	DE60232147D1 (es)
DK (1)	DK1399133T4 (es)
ES (1)	ES2324156T5 (es)
HU (1)	HU230152B1 (es)
IL (1)	IL159060A0 (es)
MX (1)	MXPA03011440A (es)
MY (1)	MY139606A (es)
NO (1)	NO333531B1 (es)
NZ (1)	NZ529968A (es)
PE (1)	PE20030069A1 (es)
PL (1)	PL212531B1 (es)
PT (1)	PT1399133E (es)
RU (2)	RU2297240C2 (es)
SI (1)	SI1399133T2 (es)
SK (1)	SK287568B6 (es)
TW (1)	TWI225416B (es)
WO (1)	WO2003002091A2 (es)
ZA (1)	ZA200309153B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2490351C (en)	2002-06-25	2011-11-01	Takeda Pharmaceutical Company Limited	Process for producing sustained-release composition
DE60315472T2 (de) *	2002-09-24	2008-04-30	Asahi Kasei Chemicals Corp.	Glycolsaüre copolymer und verfahren zu dessen herstellung
TW200529890A (en)	2004-02-10	2005-09-16	Takeda Pharmaceutical	Sustained-release preparations
TW200613012A (en) *	2004-07-02	2006-05-01	Takeda Pharmaceuticals Co	Sustained-release composition, process for producing the same and use of the same
DE602006000381T2 (de) *	2005-04-28	2008-12-18	Nipro Corp., Osaka	Bioabsorbierbare pharmazeutische Zusammensetzung enthaltend einen PLGA-Copolymer
DK1984009T3 (da)	2006-01-18	2013-01-28	Qps Llc	Farmaceutiske sammensætninger med forbedret stabilitet
CN101563068B (zh) *	2006-12-18	2013-03-20	武田药品工业株式会社	缓释组合物和其制备方法
DK3660073T3 (da)	2007-02-15	2023-09-18	Tolmar International Ltd	Poly(lactid-co-glycolid) med lav sprængning
KR101008462B1 (ko) *	2007-07-26	2011-01-14	조남열	치어류 이동용 어도 장치
KR100969641B1 (ko) *	2007-11-12	2010-07-14	민선영	저수지의 제방용 어도
KR100969642B1 (ko) *	2007-11-15	2010-07-12	민선영	하천의 보용 어도
TWI477266B (zh) *	2009-11-05	2015-03-21	Taiwan Biotech Co Ltd	連續製備微粒的方法、裝置及其收集單元
US8641900B2 (en)	2009-11-05	2014-02-04	Taiwan Biotech Co., Ltd	Method and device for continuously preparing microspheres, and collection unit thereof
EP2697361A1 (en) *	2011-04-11	2014-02-19	Cellcura Asa	Protein-free culture media products for manufacturing viral-based vaccines
US9517210B2 (en)	2012-07-12	2016-12-13	Takeda Pharmaceutical Company Limited	Method for producing microcapsule powder
RU2572992C2 (ru) *	2012-08-28	2016-01-20	Федеральное государственное бюджетное образовательное учреждение высшего образования "Курская государственная сельскохозяйственная академия имени И.И. Иванова"	Способ получения микрокапсул водорастворимых препаратов пестицидов
JP5959728B2 (ja)	2013-04-11	2016-08-02	三井化学株式会社	乳酸―グリコール酸共重合体の製造法またはその塩の製造法
RU2537173C1 (ru) *	2013-05-24	2014-12-27	Александр Александрович Кролевец	Способ получения микрокапсул гетероциклических соединений триазинового ряда
RU2537248C1 (ru) *	2013-05-24	2014-12-27	Екатерина Евгеньевна Быковская	Способ получения микрокапсул гетероциклических соединений триазинового ряда
CN105764491A (zh)	2013-12-09	2016-07-13	度瑞公司	药物活性剂复合物、聚合物复合物，以及包括其的组合物和方法
EP3131532A1 (de)	2014-04-16	2017-02-22	Veyx-Pharma GmbH	Veterinärpharmazeutische zusammensetzung und deren verwendung
TW201618783A (zh)	2014-08-07	2016-06-01	艾森塔製藥公司	以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
CN104224731A (zh) *	2014-09-11	2014-12-24	北京天晟泰丰医药科技有限公司	一种不含致敏性辅料的九肽微球的制备方法
JP5938762B1 (ja)	2015-09-01	2016-06-22	日揮株式会社	マイクロカプセル製剤及びその製造方法
CN110856690B (zh) *	2018-08-22	2024-07-02	深圳善康医药科技股份有限公司	一种植入剂包膜及干燥装置
WO2021234731A1 (en) *	2020-05-18	2021-11-25	Dr Reddy's Institute Of Life Sciences	Sustained release compositions

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS60100516A (ja)	1983-11-04	1985-06-04	Takeda Chem Ind Ltd	徐放型マイクロカプセルの製造法
JPH0678425B2 (ja)	1984-07-06	1994-10-05	和光純薬工業株式会社	重合体の新規製造法
CA1256638A (en)	1984-07-06	1989-06-27	Motoaki Tanaka	Polymer and its production
JPH0720859B2 (ja)	1985-02-07	1995-03-08	武田薬品工業株式会社	マイクロカプセルの製造法
EP0190833B1 (en)	1985-02-07	1991-03-27	Takeda Chemical Industries, Ltd.	Method for producing microcapsule
JP2551756B2 (ja)	1985-05-07	1996-11-06	武田薬品工業株式会社	ポリオキシカルボン酸エステルおよびその製造法
EP0480918A1 (en)	1988-02-10	1992-04-22	Abbott Laboratories	Reduced size lhrh analogs
US5110904A (en)	1989-08-07	1992-05-05	Abbott Laboratories	Lhrh analogs
JP2653255B2 (ja) *	1990-02-13	1997-09-17	武田薬品工業株式会社	長期徐放型マイクロカプセル
JP3200706B2 (ja)	1990-04-13	2001-08-20	武田薬品工業株式会社	生体内分解型高分子重合物
DE69129770T2 (de) *	1990-04-13	1998-11-19	Takeda Chemical Industries Ltd	Biologisch abbaubare hochmolekulare Polymere, ihre Herstellung und ihre Verwendung
CA2079509C (en) *	1991-10-01	2002-05-14	Shigeyuki Takada	Prolonged release microparticle preparation and production of the same
JP3277342B2 (ja) *	1992-09-02	2002-04-22	武田薬品工業株式会社	徐放性マイクロカプセルの製造法
TW333456B (en)	1992-12-07	1998-06-11	Takeda Pharm Ind Co Ltd	A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
NZ260909A (en) *	1993-07-05	1995-04-27	Takeda Chemical Industries Ltd	Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution
JP3761594B2 (ja) *	1993-07-05	2006-03-29	武田薬品工業株式会社	徐放性製剤の製造法
JPH08259460A (ja)	1995-01-23	1996-10-08	Takeda Chem Ind Ltd	徐放性製剤の製造法
CA2192782C (en) *	1995-12-15	2008-10-14	Nobuyuki Takechi	Production of microspheres
JPH11269094A (ja)	1998-01-16	1999-10-05	Takeda Chem Ind Ltd	徐放性組成物、その製造法および用途
US6740634B1 (en) *	1998-01-16	2004-05-25	Takeda Chemical Industries, Ltd.	Sustained release compositions, process for producing the same and utilization thereof
CN1134479C (zh) †	1998-12-15	2004-01-14	武田药品工业株式会社	制备聚合物的方法
JP3716146B2 (ja) *	1998-12-15	2005-11-16	武田薬品工業株式会社	ポリマーの製造方法
JP2002114667A (ja)	2000-10-11	2002-04-16	Ltt Institute Co Ltd	徐放性製剤用組成物、その製造法および徐放性マイクロカプセル製剤
TW200526267A (en) *	2001-06-29	2005-08-16	Takeda Chemical Industries Ltd	Controlled release composition and method of producing the same
CA2490351C (en) *	2002-06-25	2011-11-01	Takeda Pharmaceutical Company Limited	Process for producing sustained-release composition

2002
- 2002-06-25 TW TW091113853A patent/TWI225416B/zh not_active IP Right Cessation
- 2002-06-26 AR ARP020102405A patent/AR034640A1/es not_active Application Discontinuation
- 2002-06-27 PE PE2002000577A patent/PE20030069A1/es not_active Application Discontinuation
- 2002-06-27 MY MYPI20022432A patent/MY139606A/en unknown
- 2002-06-28 PL PL367491A patent/PL212531B1/pl not_active IP Right Cessation
- 2002-06-28 DK DK02738837.0T patent/DK1399133T4/da active
- 2002-06-28 CZ CZ2003-3492A patent/CZ306388B6/cs not_active IP Right Cessation
- 2002-06-28 WO PCT/JP2002/006526 patent/WO2003002091A2/en not_active Ceased
- 2002-06-28 KR KR1020097017748A patent/KR20090096755A/ko not_active Ceased
- 2002-06-28 KR KR1020097017747A patent/KR100988178B1/ko not_active Expired - Lifetime
- 2002-06-28 CN CN028130413A patent/CN1535141B/zh not_active Expired - Lifetime
- 2002-06-28 PT PT02738837T patent/PT1399133E/pt unknown
- 2002-06-28 BR BR0210572-1A patent/BR0210572A/pt not_active Application Discontinuation
- 2002-06-28 EP EP02738837A patent/EP1399133B2/en not_active Expired - Lifetime
- 2002-06-28 RU RU2004102503/15A patent/RU2297240C2/ru active
- 2002-06-28 HU HU0400382A patent/HU230152B1/hu unknown
- 2002-06-28 EP EP09155256A patent/EP2108363A1/en not_active Withdrawn
- 2002-06-28 MX MXPA03011440A patent/MXPA03011440A/es active IP Right Grant
- 2002-06-28 ES ES02738837T patent/ES2324156T5/es not_active Expired - Lifetime
- 2002-06-28 DE DE60232147T patent/DE60232147D1/de not_active Expired - Lifetime
- 2002-06-28 AT AT02738837T patent/ATE429903T1/de active
- 2002-06-28 SK SK1561-2003A patent/SK287568B6/sk unknown
- 2002-06-28 NZ NZ529968A patent/NZ529968A/en not_active IP Right Cessation
- 2002-06-28 KR KR10-2003-7017111A patent/KR20040018401A/ko not_active Ceased
- 2002-06-28 SI SI200230837T patent/SI1399133T2/sl unknown
- 2002-06-28 CA CA2451718A patent/CA2451718C/en not_active Expired - Fee Related
- 2002-06-28 US US10/479,516 patent/US20040241229A1/en not_active Abandoned
- 2002-06-28 IL IL15906002A patent/IL159060A0/xx active IP Right Grant
- 2002-06-28 AU AU2002311630A patent/AU2002311630B2/en not_active Expired
2003
- 2003-11-25 ZA ZA2003/09153A patent/ZA200309153B/en unknown
- 2003-12-19 NO NO20035737A patent/NO333531B1/no not_active IP Right Cessation
- 2003-12-22 CO CO03111730A patent/CO5540368A2/es not_active Application Discontinuation
2006
- 2006-12-05 RU RU2006143104/15A patent/RU2434644C2/ru active
2007
- 2007-12-19 US US11/960,114 patent/US8258252B2/en not_active Expired - Fee Related
2009
- 2009-07-29 CY CY20091100808T patent/CY1109272T1/el unknown
2010
- 2010-08-11 JP JP2010180145A patent/JP5491318B2/ja not_active Expired - Lifetime
2012
- 2012-02-15 JP JP2012030788A patent/JP5860300B2/ja not_active Expired - Lifetime
- 2012-08-02 US US13/564,928 patent/US20120295848A1/en not_active Abandoned
2014
- 2014-09-10 JP JP2014184482A patent/JP5931147B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
TWI225416B (en)	2004-12-21
HK1061802A1 (en)	2004-10-08
HUP0400382A3 (en)	2010-01-28
JP5931147B2 (ja)	2016-06-08
CA2451718C (en)	2011-03-15
NO333531B1 (no)	2013-07-01
US20040241229A1 (en)	2004-12-02
EP1399133A2 (en)	2004-03-24
AU2002311630B2 (en)	2007-07-19
PT1399133E (pt)	2009-06-05
MY139606A (en)	2009-10-30
DK1399133T3 (da)	2009-08-03
US20120295848A1 (en)	2012-11-22
JP2012136530A (ja)	2012-07-19
RU2004102503A (ru)	2005-03-10
PL212531B1 (pl)	2012-10-31
CA2451718A1 (en)	2003-01-09
CY1109272T1 (el)	2014-07-02
DK1399133T4 (da)	2012-07-23
ES2324156T5 (es)	2012-07-23
BR0210572A (pt)	2004-08-03
EP1399133B2 (en)	2012-05-02
JP2010280703A (ja)	2010-12-16
IL159060A0 (en)	2004-05-12
JP5860300B2 (ja)	2016-02-16
WO2003002091A3 (en)	2003-07-24
KR20090108640A (ko)	2009-10-15
AR034640A1 (es)	2004-03-03
NO20035737L (no)	2004-02-20
KR100988178B1 (ko)	2010-10-18
EP1399133B1 (en)	2009-04-29
EP2108363A1 (en)	2009-10-14
CZ20033492A3 (cs)	2005-01-12
NZ529968A (en)	2005-08-26
PL367491A1 (en)	2005-02-21
WO2003002091A2 (en)	2003-01-09
DE60232147D1 (de)	2009-06-10
SI1399133T2 (sl)	2012-08-31
RU2297240C2 (ru)	2007-04-20
KR20090096755A (ko)	2009-09-14
ATE429903T1 (de)	2009-05-15
JP2015007120A (ja)	2015-01-15
KR20040018401A (ko)	2004-03-03
HU230152B1 (hu)	2015-09-28
MXPA03011440A (es)	2004-07-01
CN1535141A (zh)	2004-10-06
RU2006143104A (ru)	2008-06-20
PE20030069A1 (es)	2003-03-17
RU2434644C2 (ru)	2011-11-27
HUP0400382A2 (hu)	2004-12-28
US20080108778A1 (en)	2008-05-08
ES2324156T3 (es)	2009-07-31
CZ306388B6 (cs)	2017-01-04
CO5540368A2 (es)	2005-07-29
ZA200309153B (en)	2005-01-26
SI1399133T1 (sl)	2009-10-31
CN1535141B (zh)	2013-04-24
JP5491318B2 (ja)	2014-05-14
US8258252B2 (en)	2012-09-04
NO20035737D0 (no)	2003-12-19
SK15612003A3 (sk)	2004-07-07

Publication	Publication Date	Title
SK287568B6 (sk)	2011-02-04	Kompozícia s trvalým uvoľňovaním, spôsob jej výroby, jej použitie, farmaceutický prípravok a spôsob výroby polyméru
US8092830B2 (en)	2012-01-10	Lactic acid polymer and process for producing the same
EP1330293B1 (en)	2006-05-17	Controlled release composition comprising lactic acid polymer, and method of producing the same
TWI481424B (zh)	2015-04-21	緩釋性組成物及其製法
AU2002311630A1 (en)	2003-05-15	Sustained-release composition comprising lactic acid-glycolic acid copolymer and process for producing the same
JP3902518B2 (ja)	2007-04-11	徐放性組成物用乳酸−グリコール酸重合体の製造法
JP5188670B2 (ja)	2013-04-24	徐放性組成物およびその製造法
JP2004155792A (ja)	2004-06-03	徐放性組成物およびその製造法
HK1061802C (en)	2009-10-30	Sustained-release composition comprising lactic acid-glycolic acid copolymer and process for producing the same
HK1061802B (en)	2009-10-30	Sustained-release composition comprising lactic acid-glycolic acid copolymer and process for producing the same
HK1056332B (en)	2006-09-08	Controlled release composition comprising lactic acid polymer, and method of producing the same
HK1056332C (en)	2006-09-08	Controlled release composition comprising lactic acid polymer, and method of producing the same